Fluoroquinolone Restriction as an Effective Antimicrobial Stewardship Intervention
Purpose of review Fluoroquinolones are a commonly prescribed antibiotic class that has come under scrutiny in recent years due to mounting evidence of association between adverse drug events, C. difficile infection and isolation of antibiotic-resistant bacteria. Recent findings Inpatient antimicrobial stewardship (AMS) programs have a toolbox of potential interventions to curb inappropriate antibiotic use, prevent antibiotic-associated adverse drug events, and avoid unnecessary costs of care. Fluoroquinolone restriction policies in the acute care setting have demonstrated beneficial effects, including decreased rates of C. difficile infection and ESBL-producing Enterobacteriaceae. However, a simple blanket restriction policy may “squeeze the antibiotic balloon” and will likely be insufficient if not implemented in conjunction with other AMS interventions. Summary There is a growing body of evidence to support formulary restriction of fluoroquinolones in the acute care setting to decrease rates of C. difficile infection and development of ESBL-producing organisms. Data on how to best implement these restrictions or how to implement outside of acute care settings is limited..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Current infectious disease reports - 20(2018), 5 vom: 23. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Claeys, Kimberly C. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
Antibiotic restriction |
| doi: |
10.1007/s11908-018-0615-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR022967931 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR022967931 | ||
| 003 | DE-627 | ||
| 005 | 20230519160708.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201006s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11908-018-0615-z |2 doi | |
| 035 | |a (DE-627)SPR022967931 | ||
| 035 | |a (SPR)s11908-018-0615-z-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.75 |2 bkl | ||
| 100 | 1 | |a Claeys, Kimberly C. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Fluoroquinolone Restriction as an Effective Antimicrobial Stewardship Intervention |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Purpose of review Fluoroquinolones are a commonly prescribed antibiotic class that has come under scrutiny in recent years due to mounting evidence of association between adverse drug events, C. difficile infection and isolation of antibiotic-resistant bacteria. Recent findings Inpatient antimicrobial stewardship (AMS) programs have a toolbox of potential interventions to curb inappropriate antibiotic use, prevent antibiotic-associated adverse drug events, and avoid unnecessary costs of care. Fluoroquinolone restriction policies in the acute care setting have demonstrated beneficial effects, including decreased rates of C. difficile infection and ESBL-producing Enterobacteriaceae. However, a simple blanket restriction policy may “squeeze the antibiotic balloon” and will likely be insufficient if not implemented in conjunction with other AMS interventions. Summary There is a growing body of evidence to support formulary restriction of fluoroquinolones in the acute care setting to decrease rates of C. difficile infection and development of ESBL-producing organisms. Data on how to best implement these restrictions or how to implement outside of acute care settings is limited. | ||
| 650 | 4 | |a Antibiotic restriction |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Extended-spectrum beta-lactamase |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Fluoroquinolones |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Hopkins, Teri L. |e verfasserin |4 aut | |
| 700 | 1 | |a Vega, Ana D. |e verfasserin |4 aut | |
| 700 | 1 | |a Heil, Emily L. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current infectious disease reports |d Heidelberg [u.a.] : Springer, 1999 |g 20(2018), 5 vom: 23. März |w (DE-627)SPR022959068 |w (DE-600)2094167-5 |x 1534-3146 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2018 |g number:5 |g day:23 |g month:03 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s11908-018-0615-z |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.75 |q ASE |
| 951 | |a AR | ||
| 952 | |d 20 |j 2018 |e 5 |b 23 |c 03 | ||